News Biogen Inc.

Equities

BIIB

US09062X1037

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-15 pm EDT			5-day change	1st Jan Change
196.8 ^USD	-0.70%		-3.98%	-23.95%

01:51pm	Argus Adjusts Biogen's Price Target to $240 From $315	MT
01:44pm	Goldman Sachs Cuts Biogen's Price Target to $393 From $400	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Argus Adjusts Biogen's Price Target to $240 From $315	07:51am	MT
Goldman Sachs Cuts Biogen's Price Target to $393 From $400	07:44am	MT
JPMorgan Cuts Biogen's Price Target to $240 From $270, Maintains Neutral Rating	Apr. 11	MT
Morgan Stanley Trims Price Target on Biogen to $339 From $346, Keeps Overweight Rating	Apr. 09	MT
Barclays Cuts Price Target on Biogen to $215 From $230, Maintains Equalweight Rating	Apr. 04	MT
Sector Update: Health Care Stocks Higher Prebell Monday	Apr. 01	MT
Sector Update: Health Care	Apr. 01	MT
Biogen Partner Eisai Submits Supplemental Biologics License Application for Leqembi to FDA	Apr. 01	MT
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	Mar. 31	PR
Dyne Therapeutics President, CEO Joshua Brumm Resigns, John Cox Named Successor; Shares Drop 7% Pre-Bell	Mar. 25	MT
Biogen : Update on European Medicines Agency Review of Lecanemab Marketing Authorization Application	Mar. 22	PU
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 21	BU
InvestorBrandMedia: Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth	Mar. 20	AQ
BIOGEN : Jefferies confirms its Buy rating on the stock	Mar. 19	CF
Transcript : Biogen Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-19-2024 10:00 AM	Mar. 19
Biogen Inc. (BIIB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	Mar. 14	BU
Voyager Therapeutics Appoints Toby Ferguson as Chief Medical Officer	Mar. 13	MT
Biogen : to Participate in the Stifel 2024 Virtual CNS Days	Mar. 12	PU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BIIB	Mar. 11	PR
AbCellera, Biogen Collaborate to Discover Treatments for Neurological Diseases	Mar. 11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biogen Inc.

Equities

BIIB

US09062X1037

Summary

Filters